# ACHIEVE P2 - HF

> **NIH NIH P50** · WAYNE STATE UNIVERSITY · 2021 · $355,529

## Abstract

Abstract
Heart failure (HF) is one of the most common, costly, and deadly diseases affecting humans. Hypertension is
the largest single risk factor for HF, accounting for over half of all new cases. Moreover, Black adults with
hypertension have a much greater risk, perhaps 20-fold, of developing HF compared with White adults.
Accordingly, early interventions to prevent HF, in particular blood pressure (BP) control, are critical. However,
implementation of effective treatments remains suboptimal among Black communities, especially in low-
income urban settings. While many factors are involved, mounting evidence shows that adverse social
determinants of heath (SDoH) such as poor access to healthcare, food insecurity, and lack of safe places for
physical activity are critical barriers to the implementation of recommended therapies. To achieve health
equity, improved strategies must be developed to overcome these negative SDoH. To better engage our at-risk
community, our team developed an innovative mobile health unit (MHU) program that uses geospatial health
and social vulnerability data to direct health services to communities in highest need, who may not otherwise
engage with traditional health care settings. Another key to preventing HF is usage of guideline-directed
medical therapy (GDMT), not only for treating high BP, but also providing medications proven to reduce HF
incidence. In particular, inhibitors of sodium-glucose transporter type 2 (SGLT2) prevent HF and loss of kidney
function in at-risk patients and recent data suggests enhanced benefit in Black patients. Yet, these are
dramatically under-utilized in Blacks, further contributing to health disparities. In Project 2 of ACHIEVE
GREATER (Addressing Cardiometabolic Health Inequities by Early Prevention in the Great Lakes Region) we
will use a pragmatic, randomized, unblinded, clinical trial to implement and test a novel intervention leveraging
our MHU platform to improve care access combined with enhanced collaborative care delivery among Black
patients with Stage A HF (defined as asymptomatic individuals with known pre-conditions such as
hypertension who are at-risk for later-stage clinical HF). The key components of our program are 1) a
personalized intervention conducted by community health workers that addresses SDoH by linking patients
with available community and social resources, and 2) pharmacist-directed therapy optimization per a
standardized GDMT protocol. This intervention will address multiple domains and levels of impact to reduce
the large gaps in care of stage-A HF patients in the Black community and prevent progression towards
symptomatic HF.

## Key facts

- **NIH application ID:** 10437397
- **Project number:** 1P50MD017351-01
- **Recipient organization:** WAYNE STATE UNIVERSITY
- **Principal Investigator:** David E Lanfear
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $355,529
- **Award type:** 1
- **Project period:** 2021-09-24 → 2026-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10437397

## Citation

> US National Institutes of Health, RePORTER application 10437397, ACHIEVE P2 - HF (1P50MD017351-01). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10437397. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*